Pomalidomide Active in Kaposi Sarcoma Regardless of HIV Status

Share this content:
Pomalidomide is active and well tolerated in patients with symptomatic Kaposi sarcoma regardless of human immunodeficiency virus status.
Pomalidomide is active and well tolerated in patients with symptomatic Kaposi sarcoma regardless of human immunodeficiency virus status.

Pomalidomide is active and well tolerated in patients with symptomatic Kaposi sarcoma regardless of human immunodeficiency virus (HIV) status, according to a study published in the Journal of Clinical Oncology.

Kaposi sarcoma is a multicentric tumor caused by Kaposi sarcoma-associated herpes virus. Among patients with Kaposi sarcoma associated with HIV, the foundation of treatment is antiretroviral therapy, but for those without HIV, the optimal treatment strategy is less defined. Researchers evaluated the activity and tolerability of the oral immunomodulatory agent, pomalidomide, in this patient population.

For the single-center, phase 1/2 study (ClinicalTrials.gov Identifier: NCT01495598), investigators enrolled 22 patients with Kaposi sarcoma, of which 68% were HIV-positive, 77% had advanced disease, and 86% had received at least 1 prior therapy excluding antiretroviral therapy. All participants received pomalidomide once daily for 21 days of each 4-week cycle in addition to daily thromboprophylactic aspirin.

Results showed that 73% (95% CI, 50-89) of patients responded to therapy, including 9 of 15 HIV-positive patients (60%; 95% CI, 32-84) and all 7 HIV-negative patients (100%; 95% CI, 59-100). Four patients achieved a complete response. Median time to response was 4 weeks.

No dose-limiting toxicities occurred during therapy. The most common adverse events were neutropenia, constipation, anemia, fatigue, and rash, with 10 patients experiencing grade 3 to 4 neutropenia.

Pomalidomide treatment was not associated with impairment in health-related quality of life occurred during treatment.

RELATED: Adding Palifosfamide to Doxorubicin Fails to Improve PFS in Sarcoma

Further trials evaluating the efficacy of pomalidomide monotherapy and in combination with cytotoxic chemotherapy among patients with Kaposi sarcoma are warranted.                   

Reference

  1. Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: A phase I/II study. J Clin Oncol. 2016 Oct 3. doi: 10.1200/JCO.2016.69.3812 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters